1. Adler, A.I., et al., Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. Bmj, 2000. 321(7258): p. 412-9.

2. Chobanian, A.V., et al., The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. Jama, 2003. 289(19): p. 2560-72.

3. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med, 1997. 157(21): p. 2413-46.

4. Bakris, G.L., et al., Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis, 2000. 36(3): p. 646-61.

5. Trevisan, R., et al., Role of insulin and atrial natriuretic peptide in sodium retention in insulin-treated IDDM patients during isotonic volume expansion. Diabetes, 1990. 39(3): p. 289-98.

6. Anderson, E.A., et al., Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest, 1991. 87(6): p. 2246-52.

7. Edwards, J.G. and C.M. Tipton, Influences of exogenous insulin on arterial blood pressure measurements of the rat. J Appl Physiol, 1989. 67(6): p. 2335-42.

8. Lodha, S., et al., Angiotensin II-induced mesangial cell apoptosis: role of oxidative stress. Mol Med, 2002. 8(12): p. 830-40.

9. Schnee, J.M. and W.A. Hsueh, Angiotensin II, adhesion, and cardiac fibrosis. Cardiovasc Res, 2000. 46(2): p. 264-8.

10. Hsueh, W.A. and M.J. Quinones, Role of endothelial dysfunction in insulin resistance. Am J Cardiol, 2003. 92(4A): p. 10J-17J.

11. Esposito, K., et al., Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. Jama, 2003. 289(14): p. 1799-804.

12. Lyon, C.J., R.E. Law, and W.A. Hsueh, Minireview: adiposity, inflammation, and atherogenesis. Endocrinology, 2003. 144(6): p. 2195-200.

13. Festa, A., et al., Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes, 2002. 51(4): p. 1131-7.

14. Wong, S.Y., G.T. McInnes, and T.M. MacDonald, Why not prescribe the best drugs for hypertension now? J Hum Hypertens, 2003. 17(7): p. 505-11.

15. Barzilay, J.I., et al., Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care, 2001. 24(4): p. 654-8.

16. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. Bmj, 1998. 317(7160): p. 713-20.

17. Lewis, E.J., et al., The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med, 1993. 329(20): p. 1456-62.

18. Brenner, B.M., et al., Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med, 2001. 345(12): p. 861-9.

19. Lewis, E.J., et al., Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med, 2001. 345(12): p. 851-60.

20. Viberti, G. and N.M. Wheeldon, Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation, 2002. 106(6): p. 672-8.

21. Dahlof, B., et al., Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 2002. 359(9311): p. 995-1003.

22. Yusuf, S., et al., Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 2000. 342(3): p. 145-53.

23. Hansson, L., et al., Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet, 1999. 353(9153): p. 611-6.

24. Hager, W.D., et al., Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction after myocardial infarction: The SAVE Study Experience. SAVE Investigators. Survival and Ventricular Enlargement. Am Heart J, 1998. 135(3): p. 406-13.

25. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. Jama, 1982. 247(12): p. 1707-14.

26. Dargie, H.J., Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet, 2001. 357(9266): p. 1385-90.

27. Pitt, B., et al., Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med, 2003. 348(14): p. 1309-21.

28. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. Jama, 2000. 283(15): p. 1967-75.

29. Wolf, G., et al., Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta. J Clin Invest, 1993. 92(3): p. 1366-72.

30. Kagami, S., et al., Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells. Kidney Int, 1997. 51(3): p. 664-71.

31. Baricos, W.H., et al., ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. Kidney Int, 1995. 47(4): p. 1039-47.

32. Adler, S., Structure-function relationships associated with extracellular matrix alterations in diabetic glomerulopathy. J Am Soc Nephrol, 1994. 5(5): p. 1165-72.

33. Gross, M.L., et al., Renal damage in the SHR/N-cp type 2 diabetes model: comparison of an angiotensin-converting enzyme inhibitor and endothelin receptor blocker. Lab Invest, 2003. 83(9): p. 1267-77.

34. Tryggvason, K. and E. Pettersson, Causes and consequences of proteinuria: the kidney filtration barrier and progressive renal failure. J Intern Med, 2003. 254(3): p. 216-24.

35. Schiffer, M., et al., Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest, 2001. 108(6): p. 807-16.

36. Sasso, F.C., et al., Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study. Diabetes Care, 2002. 25(11): p. 1909-13.

37. Hsueh, W.A., Treatment of type 2 diabetic nephropathy by blockade of the renin-angiotensin system: a comparison of angiotensin-converting-enzyme inhibitors and angiotensin receptor antagonists. Curr Opin Pharmacol, 2002. 2(2): p. 182-8.

38. Diabetic Nephropathy. Diabetes Care, 2002. 25(90001): p. 85S-89.

39. Levy, D., et al., Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation, 1994. 90(4): p. 1786-93.

40. Lindholm, L.H., et al., Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. Lancet, 2003. 362(9384): p. 619-20.

41. Braunwald, E., et al., ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol, 2002. 40(7): p. 1366-74.

42. Taylor, A.A., Is there a place for combining angiotensin-converting enzyme inhibitors and angiotensin-receptor antagonists in the treatment of hypertension, renal disease or congestive heart failure? Curr Opin Nephrol Hypertens, 2001. 10(5): p. 643-8.

43. Dzau, V.J., Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension, 2001. 37(4): p. 1047-52.

44. Hsueh, W.A. and R.E. Law, Cardiovascular risk continuum: implications of insulin resistance and diabetes. Am J Med, 1998. 105(1A): p. 4S-14S.

45. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet, 2000. 355(9200): p. 253-9.

46. Urata, H., et al., Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem, 1990. 265(36): p. 22348-57.

47. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Jama, 2002. 288(23): p. 2981-97.

48. Vuorinen-Markkola, H. and H. Yki-Jarvinen, Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus. Metabolism, 1995. 44(1): p. 85-9.

49. Paolisso, G., et al., Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients. J Hum Hypertens, 1997. 11(5): p. 307-12.

50. Bakris, G.L. and M.R. Weir, Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med, 2000. 160(5): p. 685-93.

51. Plouin, P.F., Interactions between antihypertensive agents, serum lipids and cigarette smoking in high risk hypertensive patients. J Hum Hypertens, 1989. 3 Suppl 2: p. 49-53; discussion 53-4.

52. Lakkis, J., W.X. Lu, and M.R. Weir, RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr Hypertens Rep, 2003. 5(5): p. 408-17.